



## Cumulative Index 2003

### Volume 23

March	PRION DISEASES, pages 1-256
June	PRENATAL TESTING, pages 257-568
September	GYNECOLOGIC CYTOPATHOLOGY, pages 569-780
December	MOLECULAR METHODS IN DIAGNOSTIC MICROBIOLOGY, pages 781-958

Note: Page numbers of article titles are in **boldface** type.

### A

- Abacavir, for HIV infection, resistance to, 919
- Abortion, spontaneous, human chorionic gonadotropin measurement in, 262
- Abruptio placenta, preterm delivery in, 348, 351-352
- Accuprobe, for nontuberculous mycobacteria identification, 813
- Acetylcholinesterase, in amniocentesis, 461
- Achondroplasia, prenatal diagnosis of, 487-488
- Acid elution test, for hemoglobin F, 332-333
- Acid-fast bacillus smear microscopy for *Mycobacterium tuberculosis*, 801-802  
for nontuberculous mycobacteria, 812
- Acridine derivatives, for prion diseases, 191, 199
- Acyclovir, for herpes simplex virus infections, 853
- Adenocarcinoma, gynecologic, versus adenocarcinoma in situ, 636-639
- Adenocarcinoma in situ, gynecologic, 636-639  
diagnosis of, interobserver variability and reproducibility in, 643-644  
versus benign mimics, 640-642
- Adhesion molecules, in ovarian cancer effusions, 736, 738

### Age

- gestational, determination of, in prenatal testing, 546-547  
maternal, Down syndrome screening and, 396-398, 547-548
- ahpC* gene mutations, in *Mycobacterium tuberculosis*, resistance in, 808, 824-825
- Alloimmunization, Rh, hemolytic disease of the fetus and newborn in, 319-321, 327-332
- Alpha-fetoprotein. *See also* Prenatal testing, epidemiologic monitoring of; Triple test.  
biology of, 386  
in Down syndrome screening, 397-398  
in neural tube defect screening  
historical aspects of, 386-387  
in maternal diabetes mellitus, 388-389  
in twin pregnancy, 389  
laboratory aspects of, 392-393  
MoM calculations in, 387-389  
performance evaluation in, 389  
protocol for, 390-392  
versus normal levels, 386  
in preeclampsia prediction, 424-426  
in trisomy 18 screening, 404
- Alternaria*, molecular methods for, gene amplification methods, 784
- Alveolar cells, type II (LBs), count of, in fetal lung maturity, 371-372
- Alzheimer's disease  
versus Creutzfeldt-Jakob disease, 13

- Alzheimer's disease (*continued*)  
versus Gerstmann-Sträussler-Scheinker syndrome, 66, 73
- Amniocentesis  
for bilirubin measurement, 329-331  
for cytogenetic studies, 458-463  
after chorionic villi sampling, 465  
early, 460-461  
indications for, 458  
laboratory methodology for, 461-463  
risks of, 459-460  
techniques for, 458-459  
for Down syndrome, 395-398, 402  
for fetal lung maturity testing. *See* Fetal lung maturity.  
for infection detection  
cytomegalovirus, 311  
herpes simplex virus, 309  
parvovirus B19, 302, 334-335  
toxoplasmosis, 299  
varicella, 306  
for neural tube defects, 390
- Amphotericin B, for prion diseases, 192-194
- Amplicor MTB assay, for *Mycobacterium tuberculosis* detection, 803
- Amplification refractory mutation detection system, for cystic fibrosis screening, 518-522
- Amplified fragment length polymorphism analysis, for hospital and environmental pathogens, 892
- Amprenavir, for HIV infection, resistance to, 920
- Amyloidosis  
hereditary, **65-85**  
animal studies of, 82  
in cerebral amyloid angiopathy, 69, 81  
in Gerstmann-Sträussler-Scheinker syndrome, 66-81  
amyloid characterization in, 68-69  
prion protein characterization in, 66-68  
parenchymal, 66  
with variable phenotypes, 81-82  
in scrapie, 26-27, 143  
treatment of, iododoxorubicin for, 195-196
- Anaplasmosis, 868, 875-877
- Ancillary testing, in Bethesda System 2001 recommendations, 597-598
- Anemia  
Diamond-Blackfan, prenatal diagnosis of, 335  
fetal, diagnosis of, 319-321  
in hemolytic disease of the fetus and newborn, 319-321, 327-332
- Anencephaly. *See* Neural tube defects, open.
- Angelman syndrome, prenatal diagnosis of, 473-474, 490-493
- Angiogenic molecules, in ovarian cancer effusions, 740-741
- Angiopathy, cerebral amyloid, 69, 81
- Annexins, as phospholipid-binding cofactors, 272, 282
- Anogenital cancer, human papillomavirus in, molecular techniques for, 909-911
- Anthracyclines, for prion diseases, 190, 195-196
- Antibody(ies)  
cardiolipin, in antiphospholipid syndrome, 271-274  
heterophilic, human chorionic gonadotropin test interference by, 261-262  
phospholipid. *See* Antiphospholipid syndrome.  
phospholipid-binding proteins, in antiphospholipid syndrome, 271-274  
prion, for disease treatment, 199-200
- Anticardiolipin antibodies, in antiphospholipid syndrome, tests for, 269-270
- Antiphospholipid antibodies, in preeclampsia prediction, 427-428
- Antiphospholipid syndrome, **265-293**  
antibody cross-reactions in, 270-271  
autoimmune diseases with, 267  
clinical manifestations of, 266-269  
contentious issues in, 266  
definition of, 265-266  
laboratory tests for, 269-270  
phospholipid-binding protein antibodies in, 271-274  
pregnancy and, 274-283  
antibody specificities in, 275-276  
placental pathology in, 276-283  
treatment of, 283-284  
trophoblast as target in, 277-283

- Antiretroviral agents, for HIV infection,  
resistance to, **915-928**  
evolution of, 915-916  
future directions of, 924, 926  
genotypic assays for, 917-921  
minority HIV populations and, 918  
phenotypic assays for, 921-922  
targets for, 916  
therapy selection and, 922-925  
transmission of, 916
- Antivirogram assay, for antiretroviral agent  
resistance, 922
- Arias-Stella reaction, in atypical  
endocervical cells, 634, 660
- Arthritis, in Lyme disease, diagnosis of,  
molecular tools for, 872
- Ascites, in ovarian cancer. *See* Ovarian  
cancer, effusions in.
- ASCUS/LSIL Triage Study, **570-583**  
age factors in, 579-580  
biopsy management in, 574-576,  
580-582  
colposcopy management in, 574-576,  
580-582  
diagnostic reproducibility in, 576-579  
efficacy of, 574-576  
immature metaplastic cells importance  
in, 579  
longitudinal data of, 580-582  
objectives of, 571-572  
quality control aspects of, 572-573  
rationale for, 571  
results of, 620-621, 670-671  
squamous intraepithelial lesion grade  
and, 573-574  
test parameters in, 579-580
- Aspergillus*, molecular methods for  
epidemiologic typing, 792  
gene amplification, 784-786  
targets of, 782
- Aspiration pneumonia, in chronic wasting  
disease, 149
- Aspirin  
for antiphospholipid syndrome,  
283-284  
for preeclampsia prevention, 419-420
- Ataxia, cerebellar, in variant Creutzfeldt-  
Jakob disease, 88
- Atrophy, cervicovaginal, **657-677**  
age factors in, 664  
atypia associated with, 617, 664-672  
causes of, 657-658  
drug effects on, 663-664  
hormone effects on, 658-664  
in medroxyprogesterone therapy, 661,  
671-672  
in menopause, 663, 665-669  
in postpartum state, 661, 671  
in vitamin deficiency, 664  
liquid-based specimens and, 672  
maturation index and, 658-662  
moisturizer effects on, 664  
radiation-induced, 664  
treatment of, 669-671  
versus normal cytology, 658
- Atypical glandular cells, **631-655**  
adenocarcinoma in situ, 636-644  
atypical endocervical cells  
favor neoplastic, 634-635  
not otherwise specified, 633-634  
atypical endometrial cells, 635-636  
benign mimics of adenocarcinoma in  
situ, 640-642  
Bethesda System 2001 reporting  
system for, 631-633  
classification of, 631-633  
diagnosis of, interobserver variability  
and reproducibility in, 643-644  
liquid-based preparations and, 647-648  
management algorithm for, 648-650  
prevalence of, 644-646  
significance of, 646-647
- Atypical squamous cells, **605-630**  
atrophy with, 617  
atypical repair, 616-617  
Bethesda System 2001 classification of,  
594-596  
cervicovaginal atrophic patterns and,  
664-672  
in medroxyprogesterone therapy,  
671-672  
in menopause, 665-671  
in postpartum state, 671  
human papillomavirus testing in,  
619-621, 623  
in menopause, 618-619, 622, 665-671  
management of, 621-623  
of unknown significance. *See also*  
ASCUS/LSIL Triage Study.  
atrophy and, 617, 667-670  
definition of, 665  
differential diagnosis of, 609  
human papillomavirus testing of,  
619-620, 707, 711-712  
in immunosuppression, 622  
in menopause, 618-619, 622  
in pregnancy, 622  
management of, 621-623  
morphology of, 608-611  
prevalence of, 644-646  
quality assurance considerations  
in, 623-626

- Atypical squamous cells (*continued*)  
  rescreening for, in quality control, 697-702  
  subclassification of, 605-608  
  terminology of, 605-608  
  parakeratosis, 617  
  quality assurance in, 623-626  
  reporting of, 623  
  rule out high-grade squamous intraepithelial lesions (ASC-H)  
    management of, 622-623  
    morphology of, 611-616  
  subclassification of, 579  
  terminology of, 605-608
- Autoimmune disease, reproductive failure in. *See* Antiphospholipid syndrome.
- Automation, of gynecologic cytology, 753-772  
  Bethesda System 2001  
    recommendations on, 598-599  
  for quality control, 702-703  
  historical development of, 754-756, 759-760  
  liquid-based preparation methods for, 756-759  
  need for, 753-754  
  screening, 759-768  
    AutoPap/Focal Point System, 697-698, 755, 760, 762-765  
    Cytoc Computerized Scanning Device, 767-768  
    Focal Point GS System, 765-767  
    historical development of, 759-760  
    location guided, 756, 760  
    PapNet System, 755, 761-762  
    SurePath System, 757-759  
    ThinPrep Pap Test, 757-758  
  technology selection for, 689-690
- Autonomic dysfunction, in familial fatal insomnia, 55-56
- AutoPap/Focal Point System, 697-698, 755, 760, 762-765
- Autosomal-dominant disorders, prenatal diagnosis of, 487-488
- Autosomal-recessive disorders, prenatal diagnosis of, 487
- B**
- B72.3 antibody, in ovarian cancer effusions, 730
- BACTEC systems  
  for *Mycobacterium tuberculosis* detection, 802  
  for *Mycobacterium tuberculosis* susceptibility, 804-805
- Bacterial vaginosis, cytology of, Bethesda System 2001 classification of, 592
- BAL protein, E6 protein abrogation of, 710
- BDProbeTec ET, for *Mycobacterium tuberculosis* detection, 803
- Behavioral changes, in chronic wasting disease, 148-149
- Ber-EP4 antibody, in ovarian cancer effusions, 730, 732-733
- Bethesda System 2001, 585-603  
  ancillary testing in, 597-598  
  atypical squamous cells, 594-595  
  benign cellular changes, 590, 592  
  benign endometrial cells, 596-597  
  computer-assisted diagnosis in, 598-599  
  general categorization in, 586  
  glandular lesion including atypical glandular cells, 595-596  
  history of, 585, 587  
  infections, 590, 592  
  nomenclature of, 586-587  
  recommendations for, 587, 599-601  
  specimen adequacy in, 586, 588-591  
  squamous intraepithelial lesions, 587, 593-594  
  workshop for, 587-588
- BG8 antibody, in ovarian cancer effusions, 730-731
- Bilirubin, in amniotic fluid, 329-331
- BioNumerics program, for outbreak analysis, 891
- Biopsy  
  brain, in herpes simplex virus encephalitis, 855-856  
  in cervical cytology  
    as gold standard, 694  
    in ASCUS/LSIL Triage Study, 574-576, 580-582  
  lymph node, in scrapie, 145  
  skin, fetal, for cytogenetic studies, 471  
  tonsil  
    in prion diseases, 118-119  
    in variant Creutzfeldt-Jakob disease, 89
- Bladder, outlet obstruction of, in fetus, 468-469
- Blastomyces dermatitidis*, molecular methods for, nucleic acid probes, 782-783

- BLK protein, E7 protein inactivation of, 710
- Blood, fetal  
  sampling of, for cytogenetic studies, 469-471  
  typing of, 329
- Blood culture, for cytogenetic studies, 470-471
- Blood transfusions. *See* Transfusions.
- Blood urea nitrogen, in preeclampsia, 421
- Bone marrow, failure of, in fetus, 334-335
- Borreliosis. *See* Lyme disease.
- Bovine spongiform encephalopathy, 140  
  neuroanatomic features of, 8-10  
  transmission of, to humans, 8-10  
  variant Creutzfeldt-Jakob disease and, 87, 104-106
- Brain  
  atrophy of  
    in familial fatal insomnia, 56-57  
    in Gerstmann-Sträussler-Scheinker syndrome, 73-75  
  biopsy of, in herpes simplex virus encephalitis, 855-856  
  prion diseases of. *See* Prion diseases; *specific diseases.*
- Brain-derived neurotrophic factor, in ovarian cancer effusions, 739
- Brain scan, in variant Creutzfeldt-Jakob disease, 89
- Branch migration inhibition method, in *Mycobacterium tuberculosis* resistance detection, 809-810
- Branched polyamines, for prion diseases, 191, 198-199
- Burkitt's lymphoma, Epstein-Barr virus infections associated with, molecular techniques for, 906-907
- C**
- Cadherins, in ovarian cancer effusions, 730, 732-733
- Calcium  
  in urine, in preeclampsia prediction, 429-430  
  supplementation with, for preeclampsia prevention, 420
- Calretinin, in ovarian cancer effusions, 732
- Campylobacter jejuni*, molecular epidemiology of, 888
- Cancer  
  cervical  
    cytology of. *See* Gynecologic cytology.  
    human papillomavirus in.  
      *See* Human papillomavirus.  
  infections associated with, molecular techniques for, 903-913  
    Epstein-Barr virus, 905-907  
    historical review of, 903-904  
    human papillomavirus, 909-911  
    Kaposi's sarcoma-associated herpesvirus-8, 907-909  
    types of, 904-905  
  ovarian. *See* Ovarian cancer.
- Candida*, molecular methods for epidemiologic typing, 790-794  
  gene amplification, 783-785, 787, 789  
  targets of, 782
- Capillary immunoelectrophoresis, in prion diseases, 120
- Carcinoembryonic antigen, in ovarian cancer effusions, 730
- Carcinoma, ovarian. *See* Ovarian cancer.
- Cardiolipin, antibodies to, in antiphospholipid syndrome, 269-270
- Carrageenans, for prion diseases, 188
- Castleman's disease, multicentric, herpesvirus-8 infections associated with, molecular techniques for, 907-909
- Catenins, in ovarian cancer effusions, 736
- Cattle  
  prion protein of, structure of, 214  
  spongiform encephalopathy of. *See* Bovine spongiform encephalopathy.
- Caveolin-1, in ovarian cancer effusions, 738-739
- CD14, in ovarian cancer effusions, 732-733
- CD44, in ovarian cancer effusions, 730-731
- CD45, in ovarian cancer effusions, 732-733
- Cell adhesion molecules, in preeclampsia prediction, 430-431
- Cell culture  
  of cytomegalovirus, 311  
  of enteroviruses, 845, 848-849  
  of herpes simplex virus, 308-309, 853-854

- Cell culture (*continued*)  
prion replication in, 230-232
- Central nervous system, viral infections of, molecular diagnosis of, **843-865**  
enterovirus, 844-851  
herpes simplex virus, 851-858  
JC virus, 858-859
- Centrifugation, for pulmonary surfactant analysis, 367-368
- Centromeric probes, for FISH, 475
- Centrosomes, abnormalities of, as human papillomavirus surrogate markers, 720
- Cerebellar ataxia, in variant Creutzfeldt-Jakob disease, 88
- Cerebral amyloid angiopathy, 69, 81
- Cerebrospinal fluid analysis  
in enteroviral infections, 870-875  
in herpes simplex virus encephalitis, 856-858  
in Lyme disease, 872-873  
in variant Creutzfeldt-Jakob disease, 89
- Cervical cancer  
cytology of. *See* Gynecologic cytology.  
human papillomavirus and. *See* Human papillomavirus.
- Cervicovaginal cytology. *See* Gynecologic cytology.
- CFTR* gene and product  
function of, 509  
mutations of, 506-507,  
510-512, 517  
polymorphisms of, 511-512  
preimplantation screening for, 517  
structure of, 509
- Chaperone molecules, in prion protein conversion, 230
- Chef-DR III horizontal system, for nontuberculous mycobacteria typing, 815
- Chemokines, in ovarian cancer effusions, 740-741
- Chickenpox, prenatal diagnosis of, 296, 305-307
- Chlamydia* infections, gynecologic, cytology of, Bethesda System 2001 classification of, 592
- Chlorpromazine, for prion diseases, 34, 199
- Cholesterol inhibitors, for prion diseases, 201
- Chorioamnionitis, from amniocentesis, 459-460
- Chorionic villi sampling  
for cytogenetic studies, 463-467  
indications for, 463-464  
laboratory methodology for, 466-467  
risks of, 465-466  
techniques of, 464-465  
for Down syndrome, 395-396
- Chromatography  
in hemoglobin analysis, 323-324  
in mycolic acid analysis, for nontuberculous mycobacteria detection, 813  
thin-layer, in pulmonary surfactant analysis, 368
- Chromosome(s)  
abnormalities of, cytogenetic studies of. *See* Cytogenetics.  
analysis of, in amniotic fluid, 462-463  
marker, for FISH, 458-, 476
- Chronic wasting disease, of deer and elk, 140, 148-154  
clinical features of, 148-149  
diagnosis of, 151-153  
epidemiology of, 148  
host range of, 153-154  
pathogenesis of, 153  
pathology of, 149-150  
transmission of, 154
- Cladosporium*, molecular methods for, gene amplification, 784
- Cleavase VI invader assay, in *Mycobacterium tuberculosis* resistance detection, 830
- Coagulation tests  
in antiphospholipid syndrome, 269  
in preeclampsia, 422
- Coccidioides immitis*, molecular methods for, nucleic acid probes, 782-783
- Collagen, in ovarian cancer effusions, 736
- Collagenases, in ovarian cancer effusions, 735-736
- Colomonic acid, sulfated, for prion diseases, 201
- Colony-stimulating factor-1, in ovarian cancer effusions, 741
- Colorimetric assay, for *Mycobacterium tuberculosis* susceptibility, 805

- Colposcopy  
   in ASCUS/LSIL Triage Study, 574-576, 580-582  
   in atypical glandular cell management, 650
- Computed tomography, in variant Creutzfeldt-Jakob disease, 89
- Conformation-dependent immunoassay, for protease-resistant prion proteins, 122
- Congo red, for prion diseases, 190, 194-195
- Cordocentesis, for cytogenetic studies, 469-471
- Corticotropin-releasing hormone  
   excess of, preterm delivery in, 345-347, 349-350  
   in preeclampsia prediction, 426
- Cortisol, excess of, preterm delivery in, 346-347
- Coxsackievirus infections, of central nervous system, 844-851  
   classification of, 844  
   epidemiology of, 844-845  
   molecular aspects of, 845-846  
   nucleic acid sequence-based  
     amplification detection of, 850-851  
   reverse transcriptase-polymerase chain reaction detection of, 846-850  
   traditional detection methods for, 845
- Creatinine clearance, in preeclampsia, 421
- Creutzfeldt-Jakob disease  
   hereditary, 43-54  
     deletion mutations in, 47, 54  
     diagnosis of  
       PRNP gene mutations in, 48-49  
       protein 14-3-3 type in, 111-112  
     D178N-129V haplotype, 46, 49-50  
     E200K-129M haplotype, 45-46, 48  
     E200K-129V haplotype, 46, 48-49  
     ethnic factors in, 45, 49-51  
     INS-129M haplotypes, 47  
     insertion mutations in, 52-54  
     M232R-129M haplotype, 47, 51-52  
     murine model of, **175-186**  
     mutations in, 27-29, 220  
     neuroanatomic features of, 8  
     prion proteins in, 27-29, 44, 48-54  
     T183A-129M haplotype, 46, 50-51  
     V180I-129M haplotype, 46, 51-52  
     V210I-129M haplotype, 46, 50  
   iatrogenic, 8, 129-130  
   neuropathology of, 8, 25  
   prion proteins of  
     hereditary, 48-54  
     polymorphisms of, 237  
     sporadic, 30-31  
     structures of, 102-103  
     variant, 89, 99-104  
   sporadic, 46  
   diagnosis of  
     capillary immunoelectrophoresis in, 120  
     clinical, 110-114  
     conformation-dependent immunoassay in, 122  
     infectivity assays in, 119  
     neuropathologic methods for, 116-119  
     scanning for intensely fluorescent targets in, 110  
     urine tests in, 121-122  
     versus hereditary, 115  
   epidemiology of, 13  
   from blood transfusions, 133-134  
   iatrogenic, 129-130, 133-134  
   neuropathology of, 8, 30-31  
   prion proteins of, 30-31  
   versus Alzheimer's disease, 13  
   versus hereditary Creutzfeldt-Jakob disease, 45, 52-54  
   surveillance for, 132  
   uncommon forms of, 118  
   variant, **87-108**  
     bovine spongiform encephalopathy and, 87, 104-106  
     clinical features of, 87-89  
     diagnosis of  
       clinical, 110-112  
       conformation-dependent immunoassay in, 122  
       genetic, 115  
       infectivity assays in, 120  
       neuropathologic methods for, 116-119  
       urine tests in, 121-122  
     epidemiology of, 32-33, 89-97  
     genetic factors in, 105  
     history of, 32-33  
     laboratory testing in, 89  
     neuropathology of, 8-10, 97-100  
     peripheral pathology in, 100-104  
     prion proteins of, 89, 99-104  
     transmission of, 130-131, 134-135

- Creutzfeldt-Jakob disease (*continued*)  
    uncertainties in, 105-106  
    versus Creutzfeldt-Jakob disease, 133-134  
    versus Alzheimer's disease, 13  
    versus Gerstmann-Sträussler-Scheinker syndrome, 70  
    versus variant Creutzfeldt-Jakob disease, 133-134
- Cri-du-chat syndrome, prenatal diagnosis of, 474
- Cryptococcus neoformans*, molecular methods for, gene amplification, 787
- Culture  
    blood, for cytogenetic studies, 470-471  
    of enteroviruses, 845, 848-849  
    of herpes simplex virus, 853-854  
    of nontuberculous mycobacteria, 812  
    tissue  
        of amniotic fluid, 461-462  
        of chorionic villi, 466-467
- Cyanophilic bodies, in cervicovaginal atrophy, 662
- Cyclin E, as human papillomavirus surrogate marker, 716-718
- Cystic fibrosis, **503-530**  
    birth prevalence in, 508-509  
    clinical features of, 505-506  
    epidemiology of, 503  
    ethnic variability in, 503, 508-509  
    gene of, 509-512  
        mutations in, 506-507, 510-512, 517  
    genotype/phenotype correlations in, 511-512  
    inheritance of, 506-507  
    prenatal screening for  
        confirmatory testing in, 523  
        ethical issues in, 516-517  
        expected performance in, 514-516  
        guidelines for, 524-525  
        importance of, 503-504  
        legal issues in, 516-518  
        methods for, 518-522  
        models for, 512-513  
        molecular genetic methods in, 487  
        oversight requirements in, 524-525  
        performance evaluation of, 522-523  
        pilot trials of, 513-514  
        quality assurance in, 525-526  
        social implications of, 516-518  
    prognosis for, 507  
    treatment of, 507
- Cystic hygroma fluid, cytogenetic studies of, 467
- Cytogenetics, in prenatal diagnosis, **457-480**  
    amniotic fluid for, 458-463, 465  
    chorionic villi sampling for, 463-467  
    cystic hygroma fluid for, 467  
    fetal blood for, 469-471  
    fetal skin biopsy for, 471  
    fetal urine for, 468-469  
    molecular, 473-477  
    parental blood samples for, 472-473  
    results of, 471-473
- Cytokines  
    in ovarian cancer effusions, 740-741  
    in preeclampsia prediction, 428-429  
    preterm delivery and, 351
- Cytomegalovirus infections, prenatal diagnosis of, 296, 309-311
- Cytotrophoblast, as antiphospholipid antibody target, 278, 281-283
- Cytoc Computerized Scanning Device, for cervical cytology, 767-768
- 
- D**
- Dapsone, for prion diseases, 202
- Decidual hemorrhage, preterm delivery in, 348, 351-352
- Deer, chronic wasting disease of. *See* Chronic wasting disease.
- Dehydroepiandrosterone sulfate, excess of, preterm delivery in, 347
- Delavirdine, for HIV infection, resistance to, 919
- Denaturing gradient gel electrophoresis, in *Mycobacterium tuberculosis* resistance detection, 809
- Dermatophytes, molecular methods for epidemiologic typing, 791  
    gene amplification, 785-786  
    targets of, 782
- Desmin, in ovarian cancer effusions, 732
- Diabetes mellitus  
    gestational. *See* Gestational diabetes.  
    neural tube defect screening in, MoM adjustments in, 388-389
- Diamond-Blackfan anemia, prenatal diagnosis of, 335
- Didanosine, for HIV infection, resistance to, 919



- Dideoxynucleotide cycle sequencing  
genotype assays, for antiretroviral  
agent resistance, 917-918
- Diet, for gestational diabetes, 445-446
- Differential agglutination test, in  
toxoplasmosis, 298
- DiGeorge syndrome, prenatal diagnosis of,  
474
- Dissociation-enhanced lanthanide  
fluoroimmunoassay, in prion diseases,  
120
- DNA analysis  
for ovarian cancer effusions,  
733-734  
for prenatal diagnosis. *See* Molecular  
methods, for genetic testing, in  
prenatal diagnosis.  
microarray. *See* Microarray  
technology.  
randomly amplified polymorphic  
(RAPD)  
for fungal pathogens, 792  
for hospital and environmental  
pathogens, 891-892
- DNA probes  
for herpesvirus-8, 908-909  
for hospital and environmental  
pathogens, 886-887  
with restriction fragment length  
polymorphism analysis, for  
fungal pathogens, 791
- DNA sequencing  
in *Mycobacterium tuberculosis*  
resistance detection, 807-808, 827  
in prenatal diagnosis, of genetic  
disorders, 485
- Doppel protein  
function of, 219-221  
structure of, 209-211, 215-217,  
219-220
- Doppler ultrasound, in preeclampsia  
prediction, 423-424
- Dot-blot hybridization, in *Mycobacterium  
tuberculosis* resistance detection, 831
- Down syndrome, prenatal screening for,  
395-411  
alpha-fetoprotein, 397-398  
clinical trials of, 403  
concepts of, 395-396  
epidemiologic monitoring of,  
531-551  
first-trimester, 398-403  
goals of, 395-396  
in early pregnancy, 398-399  
laboratory considerations in,  
405-408  
maternal age and, 396-398  
MoM calculation in. *See* Multiple of  
the median (MoM).  
new methods for, 398-403  
other abnormalities identified in,  
403-405  
preeclampsia prediction from,  
424-426  
reasons for, 396  
reference data for, 405-407  
risk interpretation in, 407-408  
second-trimester, 398, 402-403  
triple test in, 398  
ultrasonography in, 399-401
- Doxycycline, for prion diseases,  
196-197
- DS500, for prion diseases, 188, 192
- Duchenne muscular dystrophy, prenatal  
diagnosis of, 488-490
- Dura mater grafts, prion disease  
transmission in, 130
- 
- E**
- E-cadherins, in ovarian cancer effusions,  
730, 736
- E6 protein, human papillomavirus,  
710-711
- E7 protein, human papillomavirus,  
710-711
- E-selectin, in preeclampsia prediction, 430
- Eclampsia, definition of, 416
- Economic issues, in gynecologic cytology,  
technology selection and, 681-682,  
687-691
- Ectopic pregnancy, testing of, 260-261
- Edwards syndrome (trisomy 18), prenatal  
screening for, 404
- Efavirenz, for HIV infection, resistance to,  
919
- Effusions, in ovarian cancer. *See under*  
Ovarian cancer.
- Ehrlichiosis  
granulocytic ewingii, 877-878  
human granulocytic (anaplasmosis),  
868, 875-877  
human monocytic, 874-875  
organisms causing, 873-874

- Electroencephalography  
in Creutzfeldt-Jakob disease, 110-111  
in familial fatal insomnia, 56  
in variant Creutzfeldt-Jakob disease, 89
- Electrophoresis  
capillary, in prion diseases, 120  
in *Mycobacterium tuberculosis*  
resistance detection, 809,  
827-830  
of hemoglobin, in prenatal diagnosis,  
322-323  
pulsed-gel  
in hospital infections, 887-891  
in nontuberculous mycobacteria  
typing, 815  
in public health environment  
infections, 887-891
- Electrophoretic karyotyping, for fungal  
pathogens, 789
- Elk, chronic wasting disease of. *See* Chronic  
wasting disease.
- embB* gene mutations, in *Mycobacterium  
tuberculosis*, resistance in, 826
- Encephalitis  
enteroviral. *See* Enteroviral infections,  
of central nervous system.  
herpes simplex virus. *See* Herpes  
simplex virus infections, of  
central nervous system.
- Encephalomyelitis, in Lyme disease,  
diagnosis of, molecular tools for,  
872-873
- Encephalopathy(ies), transmissible  
spongiform. *See also* Prion diseases.  
bovine. *See* Bovine spongiform  
encephalopathy.  
mink, 139, 234-235
- Endocervical adenocarcinoma in situ, in  
Bethesda System 2001, 595-596
- Endocervical cells, atypical  
favor neoplastic, 634-635  
not otherwise specified, 633-634
- Endocervical component, in Bethesda  
System 2001, 588-589
- Endocervical hyperplasia, microglandular,  
640-641
- Endometrial cells  
atypical, 635-636  
benign, Bethesda System 2001  
classification of, 596-597
- Endothelial dysfunction, in preeclampsia  
prediction, 426-427
- Endothelins, in preeclampsia prediction,  
426-427
- Enhanced Amplified Mycobacterium  
Tuberculosis Direct Test, 803
- Entactin, in ovarian cancer effusions, 736
- Enteric nervous system, scrapie entering,  
147
- Enterobacteriaceae, molecular  
epidemiology of, 891-892
- Enteroviral infections, of central nervous  
system, 844-851  
classification of, 844  
epidemiology of, 844-845  
molecular aspects of, 845-846  
nucleic acid sequence-based  
amplification detection of,  
850-851  
reverse transcriptase-polymerase chain  
reaction detection of, 846-850  
traditional detection methods for, 845
- Enzyme immunoassay  
in HIV infection, 303-304  
in parvovirus infections, 301, 334
- Enzyme-linked immunosorbent assay  
in antiphospholipid syndrome,  
269-270  
in Down syndrome screening, 405  
in toxoplasmosis, 298-299
- Epidemiologic monitoring, of prenatal  
screening. *See* Prenatal testing,  
epidemiologic monitoring of.
- Epidemiologic typing methods, for fungal  
pathogens, 789-794  
amplification techniques, 790-794  
electrophoretic karyotyping, 789  
restriction fragment length  
polymorphism analysis,  
789-790
- Epidermolysis bullosa, fetal skin biopsy for,  
471
- Epsilon test, for *Mycobacterium  
tuberculosis* susceptibility, 805-806
- Epstein-Barr virus infections, cancer-  
associated, molecular techniques for,  
905-907
- Erythema infectiosum (parvovirus B19  
infection), prenatal diagnosis of, 296,  
299-302, 334-335
- Erythema migrans, in Lyme disease,  
diagnosis of, molecular tools  
for, 871

- Erythroid differentiation-related factor in,  
in Creutzfeldt-Jakob disease, 114
- Erythropoiesis, development of, 318-319
- Escherichia coli*, molecular epidemiology of,  
887-888, 894-895
- ESP Culture System II  
for *Mycobacterium tuberculosis*  
detection, 802  
for *Mycobacterium tuberculosis*  
susceptibility, 805
- Estriol, unconjugated. *See also* Prenatal  
testing, epidemiologic monitoring of;  
Triple test.  
assays for, 405  
in Down syndrome screening, 398  
in preeclampsia prediction, 424-426  
in trisomy 18 screening, 404
- Estrogens  
cervicovaginal atrophy and,  
658-664  
excess of, preterm delivery and, 350
- Ethambutol, resistance to, in  
*Mycobacterium tuberculosis*, 826
- Ethnic factors, in hereditary Creutzfeldt-  
Jakob disease, 45, 49-51
- Ethical issues, in cystic fibrosis prenatal  
screening, 516-517
- ETs-1 transcription factor, in ovarian  
cancer effusions, 743-745
- Ewingii granulocytic ehrlichiosis, 877-878
- Exophiala*, molecular methods for, gene  
amplification, 784
- Extracellular matrix metalloproteinase  
inducer, in ovarian cancer effusions,  
738, 741

## F

- False-positive rate, in prenatal screening  
definition of, 532  
gestational dating and, 546
- Familial Creutzfeldt-Jakob disease. *See*  
Creutzfeldt-Jakob disease, hereditary.
- Familial fatal insomnia. *See* Fatal insomnia,  
familial.
- Fas receptor and ligand, in preeclampsia  
prediction, 428-429
- Fasting, glucose studies in, in gestational  
diabetes, 448-449
- FASTPlaqueTB assay, 806

- Fatal insomnia  
familial, 47, 55-58  
diagnosis of, *PRNP* gene muta-  
tions in, 48-49  
murine model for, 175-186  
mutations in, 27-29, 220  
neuroanatomic features of, 8  
prion proteins in, 30-31  
sporadic, neuropathology of, 8,  
30-31

- Fetal lung maturity, pulmonary surfactant  
in, 361-383  
composition of, 364-365  
properties of, 366-367, 370-372  
tests for, 362, 365-367  
centrifugation in, 367-368  
chromatographic separation in,  
368  
combinations of, 372  
fluorescence polarization,  
370-371  
functional surfactant assay in,  
371  
historical aspects of, 361,  
363-364  
in oligohydramnios, 375-376  
in polyhydramnios, 375-376  
in premature rupture of  
membranes, 374-375  
in twin gestation, 373-374  
Lung Profile, 368-369  
phospholipid extraction in, 368  
physical property evaluation in,  
370-372  
racial differences in, 376  
saturated phosphatidylcholine,  
366-367, 369-370  
type II storage form (LBs),  
371-372  
visualization in, 368

- Fetomaternal hemorrhage, detection of,  
332-334

## Fetus

- blood sampling from, for cytogenetic  
studies, 469-471  
chromosomal studies of, 457-480  
cystic fibrosis screening of, 503-530  
DNA analysis of, in preeclampsia  
prediction, 431  
hematologic disorders in, testing for,  
317-343  
hypothalamic-pituitary axis activation  
in, 345-347, 349-351  
infections in, testing for. *See*  
Infections, prenatal diagnosis of,  
loss of  
in amniocentesis, 459-460  
in chorionic villi sampling, 465

- Fetus (*continued*)  
    in fetal blood sampling, 470  
    in trisomy 18, 404  
    monitoring of, in preeclampsia, 418  
    skin biopsy of, for cytogenetic studies, 471  
    urine of, cytogenetic studies of, 468-469
- Fibrinogen, in ovarian cancer effusions, 736
- Fibrinolytic activity, in preeclampsia prediction, 429
- Fibroblastic growth factor, basic, in ovarian cancer effusions, 740
- Fibronectin  
    fetal  
        in preeclampsia prediction, 426-427  
        preterm delivery and, 352-354  
    in ovarian cancer effusions, 736
- FISH. *See* Fluorescence in situ hybridization (FISH).
- Florid plaques, in variant Creutzfeldt-Jakob disease, 97-100, 116
- Flow cytometry  
    in hemoglobin F detection, 333-334  
    in ovarian cancer effusions, 732-733
- Flupirtine, for prion diseases, 201
- Fluorescence in situ hybridization (FISH), for prenatal diagnosis  
    guidelines for, 473  
    interphase, 477  
    marker chromosomes in, 476-477  
    of bladder outlet obstruction, 468-469  
    of cystic hygroma, 467  
    probes for, 474-475
- Fluorescence polarization, for pulmonary surfactant evaluation, 370-371
- Fluoroimmunoassay, dissociation-enhanced lanthanide, in prion diseases, 120
- Focal Point GS System, for cervical cytology, 765-767
- Folate deficiency, cervicovaginal epithelial effects of, 664
- Fonseca*, molecular methods for, gene amplification, 785
- Formic acid, in immunohistochemistry, in scrapie, 144
- Fragile X (FRAX A) syndrome, prenatal diagnosis of, 495-496
- Functional surfactant assay, for fetal lung maturity, 371
- Fungal pathogens, molecular methods for, **781-799**  
    electrophoretic karyotyping, 790  
    epidemiologic typing, 789-794  
    gene amplification, 783-789  
    nonamplification, 790-791  
    nucleic acid probes, 782-783  
    nucleic acid sequence analysis, 792-794  
    polymerase chain reaction, 783-789  
    RAPD assay, 792  
    restriction fragment length polymorphism analysis, 791-792  
    targets of, 781-782
- 
- G**
- Gardnerella vaginalis* infections, cytology of, Bethesda System 2001 classification of, 592
- Gastroschisis, alpha-fetoprotein levels in, 389
- Gelatinases, in ovarian cancer effusions, 735-736
- GelCompar program, for outbreak analysis, 891
- Gene amplification methods. *See also* Polymerase chain reaction.  
    for fungal pathogens, 783-789
- GeneChip technology, in *Mycobacterium tuberculosis* resistance detection, 832-834
- Genetic factors  
    in cystic fibrosis, 506-507  
    in scrapie, 19-20  
    in variant Creutzfeldt-Jakob disease, 105
- Genetic screening  
    in preeclampsia prediction, 431-432  
    molecular techniques for. *See* Molecular methods, for genetic testing.
- Genital tract infections, preterm delivery in, 347-348, 351
- Genotype kit, for nontuberculous mycobacteria identification, 814
- Genotypic resistance assays, for HIV resistance, 917-921
- Gerstmann-Sträussler-Scheinker syndrome, **161-173**

- human  
A117V-129V haplotype of, 73  
diagnosis of, *PRNP* gene  
mutations in, 48-49  
D202N-129V haplotype of, 77,  
80  
F198S-129V haplotype of, 75-79  
G131V-129M haplotype of, 73  
H187R-129V haplotype of, 74  
M232T-129M/V haplotype of,  
80-81  
mutations in, 48-49, 220-221  
neuropathology of, 8, 25  
P102L haplotype of, 162-163  
P102L-129M haplotype of, 69-70  
P102L-129M-219K haplotype of,  
70  
P102L-129V haplotype of, 70-71  
P105L-129V haplotype of, 71-72  
prion proteins of. *See* Prion  
proteins (PrPs), in  
Gerstmann-Sträussler-  
Scheinker syndrome.  
Q212P-129M haplotype of, 80  
Q217R-129V haplotype of, 80  
versus Alzheimer's disease, 66, 73
- murine  
model for, **175-186**  
mutations in, 29-30  
prion proteins in, 8, 29-30  
type P101L, 163-171  
disease transmission in,  
164-168  
infectivity in, 167, 169-170  
mutation introduction in,  
163-164  
prion protein role in,  
170-171
- Gestational age, determination of, in  
prenatal testing, 546-547
- Gestational diabetes, **443-456**  
consequences of, 444-445  
definition of, 443  
diagnostic criteria for, 443-445  
diagnostic tests for, 450-452  
epidemiology of, 443  
postpartum testing and, 452-454  
risk factors for, 446-447  
screening tests for, 446-450  
treatment of, 445-446
- Gestational hypertension, 417
- Glandular lesions, Bethesda System 2001  
classification of, 595-596
- Gliososis  
in familial fatal insomnia, 56-57  
in hereditary Creutzfeldt-Jakob  
disease, 49
- Glucose polymer challenge test, in  
gestational diabetes, 448
- Glucose testing, in gestational diabetes  
fasting, 448-449  
glucose polymer, 448  
intravenous, 451  
oral challenge, 447-448  
oral tolerance, 450-451  
postmeal, 448-449  
postpartum, 451-454  
random, 448-449
- Glycated blood proteins, in gestational  
diabetes, 449-450
- Glycoform profiles, of scrapie prion, 146
- $\beta_2$ -Glycoprotein I  
antibodies to, pregnancy  
complications and, 275-276  
as phospholipid-binding cofactor,  
272-274
- Glycosaminoglycans, sulfate, for prion  
diseases, 3,6
- Goats, scrapie of. *See* Scrapie.
- Grand MoM. *See under* Multiple of the  
median (MoM), in prenatal screening  
for neural tube defects and Down  
syndrome.
- Growth hormone, prion disease  
transmission in, 130
- Gynecologic cytology  
atypical glandular cells in, **631-655**  
atypical squamous cells in. *See*  
Atypical squamous cells.  
automation in. *See* Automation, of  
gynecologic cytology.  
Bethesda System 2001 in, **585-603**  
in atrophy, 617, **657-677**  
in human papillomavirus testing. *See*  
Human papillomavirus,  
gynecologic cytology for.  
in ovarian cancer, **727-752**  
in pregnancy, 622, 634, 646, 660-661  
molecular markers in, **707-726**  
normal cellularity in, 658  
quality control in. *See* Quality control,  
in cervical cytology.  
technology selection for, **679-692**  
clinical community involvement  
in, 684-691  
final evaluation in, 686-687  
financial factors in, 681-682,  
687-691  
method descriptions in, 680-682  
personal factors in, 687-691  
reasons for, 689-691

- Gynecologic cytology (*continued*)  
    results of, 691-692  
    within-laboratory evaluation of, 682-684

## H

- Heat shock protein polymorphisms, for nontuberculous mycobacteria identification, 813
- HELLP syndrome, 417
- Hematocrit, in preeclampsia, 421-422
- Hematologic disorders, prenatal diagnosis of, 317-343  
    anemia, 319-321, 335  
    bone marrow failure/suppression, 334-335  
    fetomaternal hemorrhage, 332-334  
    hemoglobinopathies, 321-327  
    hydrops, 319-320  
    immune hemolytic disease, 327-332  
    normal hematopoiesis and, 318-319  
    thalassemias, 321-327
- Hematopoiesis, development of, 318-319
- Hemoglobin  
    defects of, 318-319  
    embryonic, 319  
    structure of, 318
- Hemoglobin Barts, prenatal detection of, 324-326
- Hemoglobin C, prenatal detection of, 321, 323
- Hemoglobin D Punjab, prenatal detection of, 323
- Hemoglobin E, prenatal detection of, 321, 323
- Hemoglobin F  
    in adults, 323  
    Kleihauer test for, 332-333
- Hemoglobin G Philadelphia, prenatal detection of, 323
- Hemoglobin O Arab, prenatal detection of, 323
- Hemoglobinopathies, prenatal diagnosis of, 321-327
- Hemolytic disease of the fetus and newborn, diagnosis of, 319-321, 327-332
- Hemorrhage  
    decidual, preterm delivery in, 348, 351-352  
    fetomaternal, detection of, 332-334
- Heparin, for antiphospholipid syndrome, 283-284
- Herpes simplex virus infections  
    of central nervous system, 851-858  
        clinical manifestations of, 852-853  
        epidemiology of, 852-853  
        neonatal, 852-855  
        polymerase chain reaction for, 854-858  
        traditional detection methods for, 853-854  
        virology of, 851-852  
    prenatal diagnosis of, 296, 307-309
- Herpesvirus-8 infections, molecular techniques for, 907-909
- Heteroduplex analysis, in *Mycobacterium tuberculosis* resistance detection, 809-810, 829
- Heterophilic antibodies, human chorionic gonadotropin test interference by, 261-262
- Heteropolyanion 23, for prion diseases, 188
- Heterotopic pregnancy, testing of, 262
- Histologic examination, in prion diseases, 115-116
- Histoplasma capsulatum*, molecular methods for  
    epidemiologic typing, 792-793  
    gene amplification, 788  
    nucleic acid probes, 782-783
- Hodgkin's disease, Epstein-Barr virus infections associated with, molecular techniques for, 906-907
- Homocysteine, in preeclampsia prediction, 427-428
- Hormones, cervicovaginal atrophy and, 658-664
- Hospital environment, molecular epidemiology in, 885-901  
    multilocus sequence typing in, 892-893  
    pathogens involved in, 893-894  
    plasmid typing methods for, 886  
    polymerase chain reaction in, 891-892  
    pulsed-field gel electrophoresis in, 887-891  
    restriction enzymes and probe methods in, 886-887  
    single-locus sequence typing in, 892-893

- hsp* 65 PCR restriction analysis, for nontuberculous mycobacteria identification, 813
- Human chorionic gonadotropin. *See also* Prenatal testing, epidemiologic monitoring of; Triple test.  
elevation of, preterm delivery in, 350-351  
in Down syndrome screening, 398-399, 401  
in early pregnancy viability testing, 257-264  
  chemistry of, 257-258  
  ectopic, 260-261  
  heterophilic antibody interference with, 261-262  
  heterotopic, 262  
  in spontaneous abortion, 262  
  test types for, 258-259  
  timing of, 259-260  
  versus progesterone, 262-263  
  in preeclampsia prediction, 424-426  
  in trisomy 18 screening, 404
- Human granulocytic ehrlichiosis (anaplasmosis), 868, 875-877
- Human immunodeficiency virus infection  
  antiretroviral resistance in, 915-928  
  evolution of, 915-916  
  future directions of, 924, 926  
  genotypic assays for, 917-921  
  minority virus populations and, 918  
  phenotypic assays for, 921-922  
  targets for, 916  
  therapy selection and, 922-925  
  transmission of, 916  
  Kaposi's sarcoma in, herpesvirus-8 infections associated with, molecular techniques for, 907-909  
  prenatal diagnosis of, 296, 302-305
- Human monocytic ehrlichiosis, 874-875
- Human papillomavirus  
  cancer-associated, molecular techniques for, 909-911  
  gynecologic cytology for atrophy and, 669-671  
  atypical squamous cells and, 609, 619-623  
  clinical trials of. *See* ASCUS/LSIL Triage Study.  
  efficacy of, 712  
  guidelines for, 711-712  
  molecular markers for, 707-726  
    centrosomes, 720  
    cyclin E, 716-718  
    E6 protein, 710-711  
    E7 protein, 710-711  
  Hybrid Capture II Test System in, 712-713  
  in situ hybridization in, 714  
  Ki-67 protein, 719-720  
  microarray technology, 721-722  
  P16INK4a protein, 715-716  
  polymerase chain reaction in, 713-714  
  proliferating cell nuclear antigen, 720  
  surrogate, 714-722  
  telomerase, 718-719  
  pathogenesis and, 708-710  
  technology selection for, 685-687
- Hybrid II Capture II Test system, for human papillomavirus, 712-713
- Hydrops fetalis  
  bone marrow suppression in, 335  
  diagnosis of, 319-321
- Hyperchromasia, in atypical glandular cells, 633-635
- Hyperchromatic crowded groups, in cervicovaginal atrophy, 666
- Hyperglycemia, tests for. *See* Glucose testing.
- Hypertension  
  chronic, preeclampsia superimposed on, 416-417  
  gestational, 417  
  in preeclampsia, 414-417  
  in pregnancy, classification of, 415-417
- Hyperuricemia, in preeclampsia, 421
- Hypothalamic-pituitary-adrenal axis, activation of, preterm delivery in, 345-347, 349-351
- 
- I**
- Immune response, in preeclampsia, 419
- Immunization, for prion diseases, 199-200
- Immunoassays, in Down syndrome screening, 405
- Immunoblot test  
  in familial fatal insomnia, 57-58  
  in parvovirus infections, 301  
  in scrapie, 145-146
- Immunocytochemistry  
  in variant Creutzfeldt-Jakob disease, 99-100  
  of ovarian cancer effusions, 729-732

- Immunoelectrophoresis, capillary, in prion diseases, 120
- Immunofluorescence tests, in parvovirus infections, 301
- Immunoglobulin G avidity test, in toxoplasmosis, 298
- Immunohistochemistry  
in chronic wasting disease, 152  
in prion diseases, 115-116  
in scrapie, 142-144
- Immunometric assays, for alpha-fetoprotein, in neural tube defects, 392
- Immunosorbent agglutination assay, in toxoplasmosis, 298
- Immunosuppression, atypical squamous cells in, 622
- Implantation, genetic testing before, 497-498
- In situ hybridization, for human papillomavirus, 714
- Indinavir, for HIV infection, resistance to, 919
- Indirect fluorescent antibody test, in toxoplasmosis, 298
- Infections  
cancer-associated, molecular tests for, **903-913**  
gynecologic, cytology of, Bethesda System 2001 classification of, 590, 592  
prenatal diagnosis of, **295-315**  
cytomegalovirus, 296, 309-311  
herpes simplex virus, 296, 307-309  
human immunodeficiency virus, 296, 302-305  
parvovirus B19, 296, 299-302, 334-335  
summary of, 296  
toxoplasmosis, 296-299  
varicella, 296, 305-307
- Infectivity assays, in prion disease, 119-120
- inhA* gene mutations, in *Mycobacterium tuberculosis*, resistance in, 824-825
- Inhibin A  
in Down syndrome screening, 398  
in preeclampsia prediction, 424-426
- Initial-positive rate, in prenatal screening cutoff levels and, 545  
definition of, 532
- gestational dating and, 546-547  
inappropriate, 544  
initial applications of, 534-535  
maternal age and, 547-548  
monitoring of, 543-544
- INNO-LiPA assay  
for *Mycobacterium tuberculosis* resistance detection, 808, 830-831  
for nontuberculous mycobacteria identification, 814
- Insomnia, fatal. *See* Fatal insomnia.
- Insulin  
for gestational diabetes, 445-446  
resistance to, in preeclampsia prediction, 430
- Insulin-like growth factor binding protein 1, in preeclampsia prediction, 431
- Integrated Test, in Down syndrome, 402
- Integrins, in ovarian cancer effusions, 736, 738
- Intercellular adhesion molecule 1, in preeclampsia prediction, 430
- Interleukin-1, preterm delivery and, 347
- Interleukin-2, in ovarian cancer effusions, 740
- Interleukin-6, preterm delivery and, 351
- Interleukin-8, in ovarian cancer effusions, 740
- Interleukin-21, in ovarian cancer effusions, 741
- Invader assay, in *Mycobacterium tuberculosis* resistance detection, 830
- Iododoxorubicin, for prion diseases, 190, 195-196
- IS6110 typing method, for *Mycobacterium tuberculosis*, 811
- Isoniazid  
resistance to, in *Mycobacterium tuberculosis*, 807-808, 824-825, 828, 830, 834  
susceptibility to, in *Mycobacterium tuberculosis*, 834-835
- Ixodes  
in ehrlichiosis, 867, 873-878  
in Lyme disease, 867-873
- J**
- JC virus infections, of central nervous system, 858-859



**K**

Kallmann's syndrome, prenatal diagnosis of, 474

Kaposi's sarcoma, molecular techniques for, 907-909

Karyotypes, prenatal determination of  
45,X, 472  
46,XX, 472

Karyotyping, electrophoretic, for fungal pathogens, 789

*kasA* gene mutations, in *Mycobacterium tuberculosis*, resistance in, 808, 825

*katG* gene mutations, in *Mycobacterium tuberculosis*, resistance in, 824-825, 828, 830-831

Kell antigen, antibodies to, hemolytic disease of the fetus and newborn in, 329

Ki-67 protein, as human papillomavirus surrogate marker, 719-720

Kidney function tests, in preeclampsia, 420-421, 429-430

*Klebsiella pneumoniae*, molecular epidemiology of, 894

Kleihauer acid elution test, for hemoglobin F, 332-333

**Kuru**

genetic factors in, 105  
neuropathology of, 8, 25  
plaques in, 116  
scrapie resembling, 139

**L****Labor and delivery**

for preeclampsia, 418  
preterm. *See* Preterm delivery.  
rapid HIV testing during, 304

Laminin, in ovarian cancer effusions, 736

Lamivudine, for HIV infection, resistance to, 919

Lecithin/sphingomyelin ratio, for fetal lung maturity  
as gold standard, 365-366  
centrifugation for, 367-368  
in preterm rupture of membranes, 374-375  
in test combinations, 372  
in twin gestation, 373  
racial differences in, 376  
technical problems with, 363-364

versus fluorescence polarization, 370-371

Legal issues, in cystic fibrosis prenatal screening, 516-518

*Legionella pneumophila*, molecular epidemiology of, 893

Leiomyoma, Epstein-Barr virus infections associated with, molecular techniques for, 906-907

Leiomyosarcoma, Epstein-Barr virus infections associated with, molecular techniques for, 906-907

Leptin, in preeclampsia prediction, 426

Leukoencephalopathy, progressive multifocal, 858-859

Lewis antigens, in ovarian cancer effusions, 730-731

Ligase detection reaction, in *Mycobacterium tuberculosis* resistance detection, 833

LightCycler polymerase chain reaction equipment, in *Mycobacterium tuberculosis* resistance detection, 810, 831-832

Liley and Queenan charts, for amniotic fluid bilirubin, 329-332

Limb defects, in chorionic villi sampling, 465-466

Line probe assay, in *Mycobacterium tuberculosis* resistance detection, 808, 830-831

Liquid-based preparations, in gynecologic cytology. *See also* Gynecologic cytology, technology selection for.  
atypical glandular cells and, 610, 647-648  
automation and, 756-759  
in atrophy, 672

*Listeria monocytogenes*, molecular epidemiology of, 888, 894-895

Liver function tests, in preeclampsia, 422

Location guided screening, in cervical cytology, 756, 760

Lopinavir/ritonavir, for HIV infection, resistance to, 920

Lower uterine sampling, cytology of, 641-642

Lung, fetal, maturity of. *See* Fetal lung maturity.

- Lung Profile, for fetal lung maturity, 368-369
- Lupus anticoagulant, in antiphospholipid syndrome  
tests for, 269-270  
thrombosis and, 275
- Lyme disease  
clinical features of, 869-870  
molecular methods for, 870-873  
with arthritis, 872  
with bloodstream invasion, 871-872  
with cutaneous manifestations, 871  
with neurologic involvement, 872-873  
organism causing, 868-870
- Lymph node, biopsy of, in scrapie, 145
- Lymphocytosis, polyclonal, Epstein-Barr virus infections associated with, molecular techniques for, 906-907
- Lymphoid tissue, prion proteins in, in variant Creutzfeldt-Jakob disease, 100-101
- Lymphoma  
Epstein-Barr virus infections associated with, molecular techniques for, 906-907  
herpesvirus-8 infections associated with, molecular techniques for, 907-909
- Lymphoreticular system, in scrapie, 188, 200
- M**
- Mad cow disease. *See* Bovine spongiform encephalopathy; Creutzfeldt-Jakob disease, variant.
- MAGIChips, in *Mycobacterium tuberculosis* resistance detection, 833
- Magnetic resonance imaging  
in Creutzfeldt-Jakob disease, 112  
in variant Creutzfeldt-Jakob disease, 89
- Malassezia*, molecular methods for, gene amplification, 785
- Marker chromosomes, for FISH, 476
- Maternal age, Down syndrome screening and, 396-398, 547-548
- Matrix metalloproteinases, in ovarian cancer effusions, 735-737, 741
- MB/BacT System, for *Mycobacterium tuberculosis* detection, 802
- Medroxyprogesterone therapy, cervicovaginal atrophy in, 661, 671-672
- Memantine, for prion diseases, 201
- Membranes, preterm premature rupture of, fetal lung maturity tests in, 374-375
- Meningitis  
enteroviral. *See* Enteroviral infections, of central nervous system.  
in Lyme disease, diagnosis of, molecular tools for, 872-873
- Menopause  
atypical squamous cells in, 618-619, 622  
cervicovaginal atrophy in, 663, 665-669
- Menstrual cycle, cervicovaginal cellular patterns in, 660
- Mesothelium, antibodies to, in ovarian cancer effusions, 732
- Metalloproteinases, in ovarian cancer effusions, 735-737, 741
- Metastasis, from ovarian cancer, effusions and, 735-743
- Methicillin, *Staphylococcus aureus* resistant to, molecular epidemiology of, 887, 889-890, 893-894
- N-Methyl-D-aspartate antagonists, for prion diseases, 201
- MIB-1 antibody, for Ki-67 protein recognition, 719
- Mice. *See also specific diseases*, murine, prion protein of, structure of, 214
- Microarray technology  
in cancer-associated infections, 905  
in human papillomavirus testing, 721-722  
in *Mycobacterium tuberculosis* resistance detection, 810, 832-834
- Microdeletion syndromes, prenatal diagnosis of, 475
- Miller-Dieker syndrome, prenatal diagnosis of, 474
- Mink, transmissible encephalopathy of, 139, 234-235

- Minocycline, for prion diseases, 196-197
- Miscarriage, in antiphospholipid syndrome, 275
- Mitogen-activated protein kinase, in ovarian cancer effusions, 744-745
- Mixed linker polymerase chain reaction, for *Mycobacterium tuberculosis* typing, 811
- Molecular beacons, in *Mycobacterium tuberculosis* resistance detection, 810
- Molecular methods
- for antiretroviral resistance in HIV infections, **915-928**
  - for cancer-associated infections, **903-913**
  - for ehrlichiosis, 867, 873-878
  - for environmental pathogens, **885-901**
  - for fungal pathogens, **781-799**
  - for genetic testing. *See also* Cytogenetics.
- in prenatal diagnosis, 473-477, **481-502**
- direct mutation analysis in, 482
  - DNA sequencing in, 485
  - future developments in, 499
  - indirect mutation analysis in, 483
  - Northern blot in, 484
  - of nonclassic inheritance patterns, 490-493
  - of single gene disorders, 487-490
  - of trinucleotide repeat expansions, 493-496
  - polymerase chain reaction in. *See* Polymerase chain reaction.
  - preimplantation, 498-499
  - Southern blot in, 483-484
  - with maternal serum components, 496-498
- for hospital pathogens, **885-901**
- for Lyme disease, 867-873
- for *Mycobacterium tuberculosis* resistance, 806-810, **823-841**
- for nontuberculous mycobacteria, 813-815
- for outbreak situations, **885-901**
- for viral infections, of central nervous system, **843-865**
- MoM. *See* Multiple of the median.
- Monocytes, *Ehrlichia* infection of, 874-875
- Mosaicism, prenatal diagnosis of, 472
- MS-8209, for prion diseases, 193
- Multilocus enzyme typing, of nontuberculous mycobacteria, 814-815
- Multilocus sequence typing, for hospital and environmental pathogens, 892-893
- Multiple of the median (MoM), in prenatal screening for neural tube defects and Down syndrome, 405-407
- as common currency, 533
  - calculation of, 387-389
  - definition of, 532
  - gestational dating and, 546-547
  - grand
    - acceptable limits for, 538-540
    - action limits on, 537-538
    - definition of, 533
    - monitoring of, 535-537, 540  - in monitoring report, 549-550
  - new values for, 541-543
  - periodic recalculation of, 541
  - racial factors in, 548
- Muscular dystrophy, prenatal diagnosis of, 488-490
- Mutation analysis
- for antiretroviral agent resistance, 917-921
  - for prenatal diagnosis
    - direct, 482
    - indirect, 483
- MutationScreener Kit, in *Mycobacterium tuberculosis* resistance detection, 808-809
- Mycobacteria, nontuberculous
- identification of, 812-814
  - typing of, 814-815
- Mycobacterial esterases, in *Mycobacterium tuberculosis* susceptibility testing, 806
- Mycobacterial interspersed repetitive unit typing, of *Mycobacterium tuberculosis*, 812
- Mycobacterium tuberculosis*
- laboratory diagnosis of, 801-804
  - molecular epidemiology of, 887
  - resistance in, **823-841**
    - ethambutol, 826
    - isoniazid, 807-808, 824-825, 828, 830, 834
    - mechanisms of, 824-826
    - molecular test methods for, 806-810, 826-834
    - DNA sequencing, 807-808, 827

*Mycobacterium* (continued)

- dot-blot, 831
  - electrophoresis, 827-830
  - heteroduplex analysis, 809-810, 829
  - hybridization, 830-834
  - invader assay, 830
  - line probe assay, 830-831
  - microarray analysis, 810, 832-834
  - polymerase chain reaction, 827-834
  - restriction fragment length polymorphism, 828
  - RNA:RNA mismatch assay, 829-830
  - single-strand conformation polymorphism, 809, 828
  - pyrazinamide, 825-826
  - rifampin, 825, 827-834
  - streptomycin, 826
  - susceptibility testing for, 804-806, 834-835
  - typing of, molecular test methods for, 810-812
- Mycolic acid analysis, for nontuberculous mycobacteria detection, 813

**N**

- N-cadherin, in ovarian cancer effusions, 732-733
- Nasopharyngeal carcinoma, Epstein-Barr virus infections associated with, molecular techniques for, 906-907
- Needle, for amniocentesis, 458-459
- Nelfinavir, for HIV infection, resistance to, 920
- Neonates
- cervicovaginal atrophic pattern in, 659-660
  - herpes simplex virus infections of, 852-855
- Neoplasia, malignant. *See* Cancer.
- Nerve growth factor receptors, in ovarian cancer effusions, 739-740
- Natural tube defects, open, prenatal screening for, **385-394**
- alpha-fetoprotein in, 386-393
  - epidemiologic monitoring of, **531-551**
  - follow-up tests in, 390
  - laboratory aspects of, 392-393
  - MoM calculation in, 387-389. *See also*

- Multiple of the median (MoM). performance evaluation in, 389
- protocol for, 390-392

- Neurofibrillary tangles, in Gerstmann-Sträussler-Scheinker syndrome, 72-76, 79-81
- Neurologic disorders
- in familial fatal insomnia, 55-56
  - in Gerstmann-Sträussler-Scheinker syndrome, 70-82
  - in hereditary Creutzfeldt-Jakob disease
    - D178N-129V haplotype, 48
    - E200K-129V haplotype, 45
    - E200K-129V haplotype, 48
    - M232R-129M haplotype, 51
    - T183A-129M haplotype, 51
    - V180I-129M haplotype, 51
    - V210I-129M haplotype, 50
    - with deletion mutations, 54
    - with insertion mutations, 53-54
  - in Lyme disease, diagnosis of, molecular tools for, 872-873
  - in prion diseases, versus category, 7-10
  - in variant Creutzfeldt-Jakob disease, 88, 97-100
- Neutrophils, in ovarian cancer effusions, 739-740
- Nevirapine, for HIV infection, resistance to, 919
- Newborns
- cervicovaginal atrophic pattern in, 659-660
  - herpes simplex virus infections of, 852-855
- Nitric oxide, in preeclampsia prediction, 427
- Northern blot test, for prenatal diagnosis, 484
- Nosocomial infections. *See* Hospital environment.
- Nuchal translucency thickness, in Down syndrome, 399, 401-403, 406, 550
- Nuclear magnetic resonance
- of doppel structure, 215-217
  - of prion protein structure
    - normal, 211-215
    - protease-resistant, 217-219
- Nucleic acid sequence analysis
- for enteroviruses, 850-851
  - for fungal pathogens, 792-794

**O**

- Oligohydramnios, fetal lung maturity tests in, 375-376
- Oligonucleotide array analysis, for antiretroviral agent resistance, 917
- Oligonucleotide ligation, for antiretroviral agent resistance, 917
- Omphalocele, alpha-fetoprotein levels in, 389
- Oncofetal domain, preterm delivery and, 352-354
- Optical density, of amniotic fluid, in hemolytic disease of the fetus and newborn, 329-331
- Oral glucose challenge test, in gestational diabetes, 447-448
- Ovarian cancer, **727-752**  
effusions in  
adhesion molecules in, 736-738-740  
angiogenic molecules in, 740-741  
cancer-associated markers in, 735-741  
clinical significance of, 728-729  
cytokines in, 740-741  
diagnostic difficulty in, 729-735  
flow cytometry of, 732-733  
immunocytochemistry of, 729-732  
metastasis-associated markers in, 735-741  
metastatic sequence and, 741-743  
nerve growth factor receptors in, 739-740  
prognostic markers in, 741  
proteases in, 735-737  
signal transduction factors in, 743-745  
telomerase in, 733  
transcription factors in, 743-745  
treatment response and, 743-745  
epidemiology of, 727  
spreading patterns of, 727
- Oxidative stress, in preeclampsia prediction, 427-428

**P**

- p53 tumor suppressor protein, E6 protein abrogation of, 710
- Painting probes, for FISH, 475
- Papanicolaou classification, problems with, 585, 587

- Papanicolaou smear, significance of, 599-600
- Paper-strip line-probes, for antiretroviral agent resistance, 917
- PapNet System, 755, 761-762
- Parabasal squamous cells, in normal gynecologic cytology, 658
- Paracoccidioides brasiliensis*, molecular methods for, gene amplification, 784
- Paraffin-embedded tissue blot, in prion diseases, 117
- Parakeratosis, atypical or pleomorphic, in cervical cytology, 617
- Parvovirus B19 infections, prenatal diagnosis of, 296, 299-302, 334-335
- Penicillium*, molecular methods for, gene amplification, 784
- Pentosan sulfate, for prion diseases, 188-189
- Peptides, for prion diseases, 191, 197-198
- Performance evaluation. *See* Quality control.
- Phaeococcomyces*, molecular methods for, gene amplification methods, 784
- Phagocytophilum ehrlichiosis, 875-877
- Phenothiazines, for prion diseases, 191, 199
- Phenotypic assays, antiretroviral agent resistance, 921-922
- Phosphatidylcholine (lecithin). *See also* Lecithin/sphingomyelin ratio.  
antibodies to, in antiphospholipid syndrome, 279  
in pulmonary surfactant, 366-367, 369-370
- Phosphatidylethanolamine, antibodies to, in antiphospholipid syndrome, 271, 276-281
- Phosphatidylglycerol  
antibodies to, in antiphospholipid syndrome, 279  
in pulmonary surfactant, 366-369
- Phosphatidylinositol, antibodies to, in antiphospholipid syndrome, 279
- Phosphatidylserine, antibodies to, in antiphospholipid syndrome, 276, 279-282

- Phospholipid(s)  
  antibodies to. *See* Antiphospholipid syndrome.  
  binding proteins of, antibodies to, 271-274  
  in pulmonary surfactant. *See* Fetal lung maturity, pulmonary surfactant in.
- Phthalocyanines, for prion diseases, 197
- Phytoestrogens, cervicovaginal epithelial effects of, 664
- P16INK4a protein, as human papillomavirus surrogate marker, 715-716
- Pituitary gland extracts, prion disease transmission in, 130
- Placenta  
  abruption of, preterm delivery in, 348, 351-352  
  ischemia of, preeclampsia and, 418, 427-428  
  pathology of, in antiphospholipid syndrome, 276-283  
  proteins of, in preeclampsia prediction, 424-426
- Placenta growth factor, in preeclampsia prediction, 426
- Plaques, florid, in variant Creutzfeldt-Jakob disease, 97-100, 116
- Plasmid typing, for hospital and environmental pathogens, 886
- Plasminogen activator inhibitors, in ovarian cancer effusions, 741
- Platelet count, in preeclampsia, 422
- pncA* gene mutations, in *Mycobacterium tuberculosis*, resistance in, 807, 825-826
- Pneumocystis carinii*, molecular methods for epidemiologic typing, 793  
  gene amplification, 783, 786-787  
  targets of, 782
- Pneumonia  
  aspiration, in chronic wasting disease, 149  
  in variant Creutzfeldt-Jakob disease, 100
- Point mutation assays, for antiretroviral agent resistance, 917
- Poliomyelitis, epidemiology of, 844-845
- Polyamines, branched, for prion diseases, 191, 198-199
- Polyanions, for prion diseases, 188-190, 192
- Polyhydramnios, fetal lung maturity tests in, 375-376
- Polymerase chain reaction  
  for anaplasmosis, 868  
  for antiretroviral agent resistance, 917  
  for ehrlichiosis, 868, 874-878  
  for enteroviruses, 846-850  
  for environmental pathogens, 891-892  
  for Epstein-Barr virus, 906-907  
  for fungal pathogens, 783-789  
    conventional, 783-786  
    multiplex, 786-787  
    nested, 787-788  
    real-time, 788-789  
  for herpes simplex virus, 854-858  
  for herpesvirus-8, 908-909  
  for hospital and environmental pathogens, 891-892  
  for human papillomavirus, 713-714, 909-910  
  for JC virus, 858-859  
  for Lyme disease, 868, 870-873  
  for *Mycobacterium tuberculosis* detection, 803-804  
    resistance, 827-834  
    typing, 811  
  for prenatal diagnosis  
    of cytomegalovirus infections, 311  
    of genetic disorders, 485  
    of herpes simplex virus infections, 306  
    of parvovirus infections, 302, 335  
    of toxoplasmosis, 299  
    of varicella, 306  
  for public health outbreaks, 891-892  
  mixed linker, for *Mycobacterium tuberculosis* typing, 811  
  real-time  
    for enteroviruses, 850  
    for Epstein-Barr virus, 907  
  reverse-transcriptase  
    for enteroviruses, 846-850  
    for Epstein-Barr virus, 906
- Polyneuropathy, in Lyme disease, diagnosis of, molecular tools for, 872-873
- Polysomnography, in familial fatal insomnia, 56
- Porphyrins, for prion diseases, 197
- Positron emission tomography, in familial fatal insomnia, 56

- Postpartum state, cervicovaginal atrophy in, 661, 671
- Prader-Willi syndrome, prenatal diagnosis of, 473-474, 490-493
- Preeclampsia, **413-442**  
 chronic hypertension superimposed on, 416-417  
 definitions of, 415-417  
 diagnostic criteria for, 415-417  
 epidemiology of, 414  
 etiology of, 418-419  
 in antiphospholipid syndrome, 274-275, 282-283  
 in HELLP syndrome, 417  
 laboratory tests for, 420-422  
 prediction of, 422-432  
   cytokines in, 428-429  
   Doppler ultrasound in, 423-424  
   endothelial dysfunction in, 426-427  
   fat cell DNA testing in, 431  
   fibrinolytic activity in, 429  
   genetic screening in, 431-432  
   insulin resistance in, 430  
   oxidative stress in, 427-428  
   placental markers in, 424-426  
   platelet function in, 428  
   renal function in, 429-430  
   trophoblast invasion in, 430-431  
 prevention of, 419-420  
 recurrence risk of, 418  
 risk factors for, 414-415  
 treatment of, 418
- Preeclampsia-eclampsia, definition of, 415-416
- Pregnancy  
 antiphospholipid syndrome in, **265-293**  
   atypical glandular cells in, 634, 646  
   atypical squamous cells in, 622  
   cervicovaginal cellular patterns in, 660-661  
   early, viability of, testing of, **257-264**  
   ectopic, testing of, 260-261  
   gestational diabetes in, **443-456**  
   heterotopic, testing of, 262  
   infections in, testing for. *See* Infections, prenatal diagnosis of.  
   preeclampsia in. *See* Preeclampsia.
- Pregnancy-associated plasma protein A  
 in Down syndrome, 399, 401-402, 405-406  
 in preeclampsia prediction, 426
- Preimplantation genetic testing, 497-498
- Premature rupture of membranes, preterm, fetal lung maturity tests in, 374-375
- Prenatal interphase FISH, 477
- Prenatal testing  
 cytogenetics in, **457-480**  
 epidemiologic monitoring of, **531-551**  
   challenges in, 531  
   cutoff levels in, 545  
   factors affecting, 544  
   gestational dating for, 546-547  
   historical aspects of, 533-534  
   initial applications of, 534-535  
   initial-positive rate monitoring in, 543-544  
   marker selection for, 545  
   maternal age distribution and, 547-548  
   maternal weight distribution and, 548  
   multiple of the median in  
   action limit definition on, 537-538  
   as common currency, 533  
   limits on, 538-540  
   monitoring of, 535-537, 540-541  
   new values for, 541-543  
   periodic recalculation of, 541  
   racial factors in, 548  
   reporting of, 549-550  
   terminology of, 532-533  
 for antiphospholipid syndrome, **265-293**  
   for autoimmune disease, **265-293**  
   for cystic fibrosis, 487, **503-530**  
   for Down syndrome, **395-411, 531-551**  
   for early pregnancy viability, **257-264**  
   for fetal lung maturation, **361-383**  
   for genetic defects, **481-502**  
   for gestational diabetes, **443-456**  
   for hematologic disorders, **317-343**  
   for infectious disease, **295-315**  
   for neural tube defects, **385-394, 531-551**  
   for preeclampsia, **413-442**  
   for preterm delivery risk, **345-360**
- Preterm delivery, **345-360**  
 biochemical markers of, 349-354  
   decidual hemorrhage, 351-352  
   fetal fibronectin, 352-354  
   genital tract infection, 351  
   hypothalamic-pituitary axis hormones, 349-351  
   uterine distention, 352  
 pathogenesis of, 345-349  
 premature membrane rupture in, fetal lung maturity tests in, 374-375

- Primer-extension-based sequence scanning,  
in *Mycobacterium tuberculosis*  
resistance detection,  
833-834
- Prion diseases. *See also specific diseases.*  
amyloidosis and. *See Amyloidosis.*  
categories of, 7-10  
diagnosis of, **109-127**  
clinical, 110-114  
genetic, 114-115  
infectivity assays in, 119-120  
neuropathologic methods for,  
115-119  
protease-resistant prion protein  
assays in, 120-123  
threshold of detection in,  
123-124  
emerging, 32-33  
familial, murine model of, **175-186**  
construction of, 176  
neuropathology of, 177-179  
prion proteins in, 179-184  
symptoms in, 177  
historical review of, 1-2  
incubation time of, 26  
infectious, phenotypes of, 26-27  
list of, 1. *See also specific diseases.*  
murine models for, 13-18  
pathogenesis of, 11-13, 25-26  
phenotypes of, 23-32  
prion proteins in. *See Prion proteins*  
(PrPs).  
protease-resistant prion protein  
accumulation in, 25  
species barriers in, 26  
transmission of  
in blood transfusions, 101-102,  
**129-137**  
interspecies and intraspecies,  
235-240  
treatment of, 32-34, **187-208**  
acridine derivatives for, 191, 199-200  
anti-prion antibodies for, 191,  
199-200  
based on prion protein  
conversion, 240-242  
branched polyamines for, 191,  
198-199  
cholesterol inhibitors for, 201  
computational chemistry drugs  
for, 201  
Congo red for, 190, 194-195  
dapson for, 202  
iododoxorubicin for, 190,  
195-196  
lymphoreticular system and, 200  
N-methyl-D-aspartate  
antagonists for, 201  
peptides for, 191, 197-198  
phenothiazines for, 191, 199  
polyanions for, 188-190, 192  
polyene antibiotics for, 190,  
192-194  
sulfated colominic acid for, 201  
tetracyclines for, 191, 196-197  
tetrapyrroles for, 197
- Prion hypothesis, 209, 228-230
- Prion proteins (PrPs)  
amyloidosis and. *See Amyloidosis.*  
antibodies to, for disease treatment,  
199-200  
bovine, structure of, 214  
characteristics of, 10-11  
function of, normal, 217-219  
in cerebral amyloid angiopathy, 69  
in chronic wasting disease, 150-154  
in Creutzfeldt-Jakob disease  
polymorphisms of, 237  
sporadic, 30-32  
structures of, 102-103  
in familial fatal insomnia, 27-28,  
57-58  
in Gerstmann-Sträussler-Scheinker  
syndrome, 29-30, 220-221  
animal transmission studies of,  
82  
characterization of, 66-68  
murine model of, 167, 169-171  
in hereditary Creutzfeldt-Jakob  
disease, 27-29  
D178N-129V haplotype, 50  
E200K-129M haplotype, 48-49  
M232R-129M haplotype, 52  
T183A-129M haplotype, 51  
V180I-129M haplotype, 52  
V210I-129M haplotype, 50  
with deletion mutations, 54  
with insertion mutations, 54  
in murine model, **175-186**  
in scrapie, 142-147  
in sheep, structure of, 214  
in sporadic Creutzfeldt-Jakob  
syndrome, 30-32  
in sporadic fatal insomnia, 30-31  
in variant Creutzfeldt-Jakob disease,  
89, 97, 99-104  
murine, structure of, 214  
normal (cellular)  
function of, 217-219  
in vitro conversion to pathologi-  
cal isoforms, **227-246**  
cell-free, 232-240  
in cell culture, 230-232  
process of, 228-230  
therapeutic implications of,  
240-242  
polymorphisms of, 228-230



- structure of, 1-4, 10-11, 217-219
- polymorphisms in, interspecies and intraspecies transmissibility and, 235-240
- propagation of, 18-23
- protease-resistant
  - accumulation of, 27-32
  - aggregation of, 21-23
  - capillary immunoelectrophoresis for, 120
  - conversion from normal proteins
    - in vitro, **227-246**
    - in vivo, 4-5, 11-13, 18-24
  - detection of, 109-110
  - dissociation-enhanced lanthanide fluoroimmunoassay for, 120
  - immunohistochemistry of, 115-116
  - in hereditary Creutzfeldt-Jakob disease, 44, 48-54
  - in tonsillar biopsy, 118-119
  - in variant Creutzfeldt-Jakob disease, 89, 97, 99-104
  - in vitro conversion from normal proteins, **227-246**
    - cell-free, 232-240
    - in cell culture, 230-232
    - process of, 228-230
    - therapeutic implications of, 240-242
  - in vivo conversion from normal proteins, 4-5, 11-13, 18-24
  - infectivity assays with, 118-119
  - neuroanatomic distribution of, 27-32
  - paraffin-embedded tissue blot test for, 117
  - properties of, 4-7
  - protein-misfolding cyclic amplification for, 121
  - structure of, 10-11
  - types of, 44, 46-47
  - Western blot test for, 117-118
- protein X binding site of, 19-20
- strain variation in, 23-32, 234-235
- structures of, 10-11, **209-225**
  - flexible tail, 213
  - globular domain, 212-213
  - human versus other species, 214
  - normal, 217-219
  - recombinant, 211-214
  - versus doppel, 209-211, 215-217, 219-220
- Prion rods (scrapie-associated fibrils), 118
- PRNP* gene
  - discovery of, 2
  - mutations of, 2
    - detection of, 48-49, 118
  - in familial fatal insomnia, 27-29, 55-58
  - in hereditary Creutzfeldt-Jakob disease, 27-29, 43-54
  - prion protein amyloidosis. *See* Amyloidosis, hereditary.
- Prnp-Prnd* gene complex, in prion disease animal models, 15-18
- Probes, for FISH, 474-475
- Progesterone
  - cervicovaginal atrophy and, 662-663
  - for early pregnancy viability testing, 262-263
- Progressive multifocal leukoencephalopathy, 858-859
- Proliferating cell nuclear antigen, as human papillomavirus surrogate marker, 720
- Prostaglandins, in excess corticotropin-releasing hormone production, 346
- Proteases, in ovarian cancer effusions, 735-737
- Protein(s), 14-3-3 type, in Creutzfeldt-Jakob disease, 111-112
- Protein array technology, in human papillomavirus testing, 721-722
- Protein C, as phospholipid-binding cofactor, 272
- Protein-misfolding cyclic amplification, in prion diseases, 121, 233-234
- Proteinuria, in preeclampsia, 414-417, 420-421
- Prothrombin, as phospholipid-binding cofactor, 272-273
- PrP<sup>C</sup>. *See* Prion proteins (PrPs), normal (cellular).
- PrP<sup>res</sup>. *See* Prion proteins (PrPs), protease-resistant.
- PrP<sup>Sc</sup>. *See* Prion proteins (PrPs), protease-resistant.
- Pruritus, in scrapie, 141
- Psychiatric disorders, in variant Creutzfeldt-Jakob disease, 88
- Public health environment, molecular epidemiology in, **885-901**
  - multilocus sequence typing in, 892-893
  - pathogens involved in, 894-895
  - plasmid typing methods for, 886
  - polymerase chain reaction in, 891-892

- Public health environment (*continued*)  
pulsed-field gel electrophoresis in,  
887-891  
restriction enzymes and probe  
methods in, 886-887  
single-locus sequence typing in,  
892-893

Pulmonary surfactant. *See* Fetal lung  
maturity, pulmonary surfactant in.

Pulsed-gel electrophoresis, for  
nontuberculous mycobacteria typing,  
815

Pyrazinamide, resistance to, in  
*Mycobacterium tuberculosis*, 807, 810

## Q

Quad test, in Down syndrome, 398-399,  
401-404, 409

Quality assurance, in cystic fibrosis  
screening, 525-526

Quality control, in cervical cytology,  
693-706

ASCUS/LSIL Triage Study and,  
572-573

atypical squamous cells and, 623-626

automated slide selection in, 702-703

AutoPap/Focal Point System, 764

blinded rapid rescreening in, 699-700

directed rescreening in, 695-697

goals of, 693-694

gold standards in, 694

interlaboratory rescreening in,  
701-702

masked rescreening in, 697-699

PapNet System, 761-762

seeding of abnormal slides in, 700-701

sensitivity measures in, 694-703

surrogate markers in, 702

Quinacrine, for prion diseases, 34, 199

## R

Racial factors

in fetal lung maturity tests, 376

in prenatal testing results, 548

Radiation injury, cervicovaginal atrophy in,  
664

Radiculoneuritis, in Lyme disease, diagnosis  
of, molecular tools for, 872-873

Radioimmunoassay  
in Down syndrome screening, 405  
in parvovirus infections, 301

Randomly amplified polymorphic DNA  
(RAPD) assays

for fungal pathogens, 792  
for hospital and environmental  
pathogens, 891-892  
for nontuberculous mycobacteria  
typing, 815

Rep-polymerase chain reaction, for hospital  
and environmental pathogens,  
891-892

Repair cells, atypical, in cervical cytology,  
616-617

Replens, cervicovaginal epithelial effects of,  
664

Rescreening, in cervical cytology. *See*  
Quality control, in cervical cytology.

Resistance

to antiretroviral drugs, in HIV  
infection. *See* Antiretroviral  
agents, for HIV infection,  
resistance to.

to antituberculous therapy. *See*  
*Mycobacterium tuberculosis*,  
resistance in.

Restriction fragment length polymorphism  
analysis

for fungal pathogens, 789-790

for hospital and environmental  
pathogens, 886-887

for *Mycobacterium tuberculosis*  
resistance, 828

for *Mycobacterium tuberculosis* typing,  
811

for nontuberculous mycobacteria  
identification, 813-814

Retinoblastoma tumor suppression  
proteins, E7 protein inactivation of, 710

Revised-positive rate, in prenatal screening,  
definition of, 532

Rh antigen, sensitization to, hemolytic  
disease of the fetus and newborn in,  
319-321, 327-332

Ribotyping, for hospital and environmental  
pathogens, 886-887

Rifampin

resistance to, in *Mycobacterium*  
*tuberculosis*, 825, 827-834

susceptibility to, in *Mycobacterium*  
*tuberculosis*, 834-835

Ritonavir, for HIV infection, resistance to,  
919

RNA. RNA mismatch assay, in  
*Mycobacterium tuberculosis* resistance  
detection, 829-830

Robertsonian translocations, prenatal diagnosis of, 473

*rpoB* gene mutations, in *Mycobacterium tuberculosis*, resistance in, 808-810, 825-826, 829-834

*rspL* gene mutations, in *Mycobacterium tuberculosis*, resistance in, 826

## S

Sabin-Feldman dye test, in toxoplasmosis, 298-299

*Saccharomyces*, molecular methods for epidemiologic typing, 791  
gene amplification, 785

Saliva, estrogen in, preterm delivery and, 350

*Salmonella*, molecular epidemiology of, 886, 888, 894-895

Saquinavir, for HIV infection, resistance to, 919

Sarcoma, Kaposi's, molecular techniques for, 907-909

Scanning for intensely fluorescent targets, in prion diseases, 110

Scrapie, 140-147  
amyloidosis in, 26-27  
clinical features of, 141  
diagnosis of, 143-146  
epidemiology of, 140-141  
genetic factors in, 19-20  
incubation time of, 26  
murine models of, 165-166  
neuropathology of, 8, 25  
pathogenesis of, 146-147  
pathology of, 141-143  
prion proteins of, polymorphisms of, 237-240  
treatment of  
branched polyamines for, 191, 198-199  
Congo red for, 194-195  
peptides for, 191, 197-198  
polyanions for, 188-189  
polyene antibiotics for, 192-193  
prion antibodies for, 199-200  
tetrapyrroles for, 197

Scrapie-associated fibrils (prion rods), 118

*Scytalidium*, molecular methods for, epidemiologic typing, 791

Sensitivity, of gynecologic cytology, measures of, 694-703

Septi-Chek system, for *Mycobacterium tuberculosis* detection, 802

Serum Integrated Test, in Down syndrome, 402-403

## Sheep

prion protein of, structure of, 214  
scrapie of. *See* Scrapie.

*Shigella*, molecular epidemiology of, 888

Sickle cell disease, prenatal diagnosis of, 321-323, 327

SIFT (scanning for intensely fluorescent targets), in prion diseases, 110

Single-locus sequence typing, for hospital and environmental pathogens, 892-893

Single-strand conformation polymorphism, in *Mycobacterium tuberculosis* resistance detection, 809, 828

## Skin

biopsy of, for fetal cytogenetic studies, 471

Lyme disease manifestations in, diagnosis of, molecular tools for, 871

Sleep disorders, in fatal insomnia. *See* Fatal insomnia.

Smith-Lemli-Opitz syndrome, prenatal screening for, 404-405

Smith-Magenis syndrome, prenatal diagnosis of, 474

Social implications, of cystic fibrosis prenatal screening, 516-518

Southern blot test, for prenatal diagnosis, 483-484

Spacer oligonucleotide typing, of *Mycobacterium tuberculosis*, 811-812

Spina bifida. *See* Neural tube defects, open.

Spirochetemia, in Lyme disease, diagnosis of, molecular tools for, 871-872

Spoligotyping, of *Mycobacterium tuberculosis*, 811-812

## Spongiform changes

in familial fatal insomnia, 57-58  
in Gerstmann-Sträussler-Scheinker syndrome, 70, 73

in hereditary Creutzfeldt-Jakob disease  
D178N-129V haplotype, 49-50

- Spongiform changes (*continued*)  
M232R-129M haplotype, 51-52  
T183A-129M haplotype, 51  
V180I-129M haplotype, 51-52  
in variant Creutzfeldt-Jakob disease, 97-100
- Spongiform encephalopathy(ies), transmissible. *See also* Prion diseases, bovine. *See* Bovine spongiform encephalopathy.  
mink, 139, 234-235
- Squamous cells  
atypical. *See* Atypical squamous cells, in cervicovaginal atrophy. *See* Atrophy, cervicovaginal.  
in normal gynecologic cytology, 658
- Squamous intraepithelial lesions, gynecologic. *See also* ASCUS/LSIL Triage Study.  
atrophy and, 668-669  
Bethesda System 2001 classification of, 593-594  
prevalence of, 644-646  
rescreening for, in quality control, 694-702  
versus adenocarcinoma in situ, 638-639  
versus atypical squamous cells, 606-617
- Squamous metaplasia, of cervix, 611-614
- Staphylococcus aureus*, methicillin-resistant, molecular epidemiology of, 887, 889-890, 893-894
- Stavudine, for HIV infection, resistance to, 919
- Steroid sulfatase deficiency, prenatal diagnosis of, 474
- Streptococcus pyogenes*, molecular epidemiology of, 893
- Streptomycin, resistance to, in *Mycobacterium tuberculosis*, 826
- Stress, preterm delivery in, 345-347, 349-351
- Stromal cells, endometrial, cytology of, 642
- Subtelomeric probes, for FISH, 474-475
- Superfect, for prion diseases, 198-199
- SurePath System, for cervical cytology, 757-759
- Surfactant, pulmonary. *See* Fetal lung maturity, pulmonary surfactant in.
- Susceptibility testing, of *Mycobacterium tuberculosis*, molecular test methods for, 834-835
- Syncytiotrophoblast, as antiphospholipid antibody target, 278, 282
- Synovial fluid, molecular analysis of, in Lyme disease, 872
- 
- T**
- "Taffy pull" morphology, in gynecologic cytology, 640
- TAG-72, in ovarian cancer effusions, 730
- Tamoxifen, cervicovaginal epithelial effects of, 663-664
- Tau protein, in Creutzfeldt-Jakob disease, 113-114
- Telomerase  
as human papillomavirus surrogate marker, 718-719  
in ovarian cancer effusions, 733
- Telomeric repeat amplification protocol, in human papillomavirus testing, 718-719
- Temperature-mediated heteroduplex analysis, in *Mycobacterium tuberculosis* resistance detection, 809-810
- Tenascin, in ovarian cancer effusions, 736
- Tenofovir, for HIV infection, resistance to, 919
- Tetracyclines, for prion diseases, 191, 196-197
- Tetrapyrroles, for prion diseases, 197
- Thalassemias, prenatal diagnosis of, 321-327
- ThinPrep Pap Test, 757-758
- Thrombocytopenia, in preeclampsia, 422
- Thrombosis, in antiphospholipid syndrome, 266-269  
in placenta, 276-283  
systemic, 278
- Thromboxanes, in preeclampsia prediction, 428
- Tick-borne diseases  
ehrlichiosis, 867, 873-878  
Lyme disease, 867-873
- Tissue culture  
of amniotic fluid, 461-462

- of chorionic villi, 466-467
  - Tissue factor, excess of, preterm delivery in, 348
  - Tissue inhibitors of metalloproteinases, in ovarian cancer effusions, 735-736
  - Tonsil, biopsy of
    - in prion diseases, 118-119
    - in variant Creutzfeldt-Jakob disease, 89
  - Toxoplasmosis, prenatal diagnosis of, 296-299
  - Transcription factors, in ovarian cancer effusions, 743-745
  - Transformation zone, in Bethesda System 2001, 588-589
  - Transforming growth factor- $\beta$ , in preeclampsia prediction, 429
  - Transforming growth factor- $\beta$ 2, in ovarian cancer effusions, 740
  - Transfusions, prion disease transmission in, 129-137
    - animal studies of, 131
    - Creutzfeldt-Jakob disease, 133-134
    - epidemiology of, 131-133
    - evidence for, 131-133
    - hazard identification in, 129-131
    - policy options for, 134-135
    - variant Creutzfeldt-Jakob disease, 101-102
  - Transitional cell metaplasia, in cervicovaginal atrophy, 666
  - Transmissible mink encephalopathy, 139, 234-235
  - Transmissible spongiform encephalopathies. *See* Prion diseases; *specific diseases.*
  - Trichophyton*, molecular methods for epidemiologic typing, 792
    - gene amplification, 786
  - Trichosporon*, molecular methods for, 784
  - Triglycerides, in preeclampsia prediction, 427-428
  - Trinucleotide repeat expansions, prenatal diagnosis of, 493-496
  - Triple test
    - in Down syndrome screening, 398-399, 401, 409
    - in preterm delivery prediction, 350-351
    - in Smith-Lemli-Opitz syndrome, 405
    - in trisomy 18 screening, 404
  - Trisomy 18 (Edwards syndrome), prenatal screening for, 404
  - Trisomy 21. *See* Down syndrome.
  - Trophoblast
    - as antiphospholipid antibody target, 278-283
    - evaluation of, in preeclampsia prediction, 430-431
  - TruGene kit, for antiretroviral agent resistance, 917-918
  - Tuberculosis, organism causing. *See* *Mycobacterium tuberculosis.*
  - Tumor necrosis factor- $\alpha$ 
    - in genital tract infections, preterm delivery and, 347-348
    - in preeclampsia prediction, 428
  - Twin pregnancy
    - alpha-fetoprotein levels in, 389
    - fetal lung maturity tests in, 373-374
  - Tyrosine kinase receptors, in ovarian cancer effusions, 739-740
- 
- U**
- Ultrasonography
    - in amniocentesis, 458-459
    - in Down syndrome, 399-403, 406
    - in hemolytic disease of the fetus and newborn, 332
    - in infection detection
      - cytomegalovirus, 310
      - herpes simplex virus, 308
      - HIV, 303
      - parvovirus B19, 300-301
      - toxoplasmosis, 297
      - varicella, 306
    - in neural tube defects, 390
    - in preeclampsia prediction, 423-424
  - Umbilical cord blood sampling, for cytogenetic studies, 469-471
  - Uniparental disomy, prenatal diagnosis of, 473
  - Universal heteroduplex analysis, in *Mycobacterium tuberculosis* resistance detection, 829
  - Uric acid, excess of, in preeclampsia, 421
  - Urine
    - Borrelia* nucleic acids in, 873
    - fetal, cytogenetic studies of, 468-469
    - protease-resistant prion proteins in, 121-122

- Uteroplacental circulation  
  evaluation of, in preeclampsia  
    prediction, 423-424  
  insufficiency of, preterm delivery in,  
    350-351
- Uterus, overdistention of, preterm delivery  
  in, 348-349, 352

---

**V**

- Vacuolar degeneration, prion protein  
  distribution and, 27
- Vaginal cytology. *See* Gynecologic  
  cytology.
- Variant Creutzfeldt-Jakob disease. *See*  
  Creutzfeldt-Jakob disease, variant.
- Varicella, prenatal diagnosis of, 296,  
  305-307
- Vascular cell adhesion molecule 1, in  
  preeclampsia prediction, 430
- Vascular endothelial growth factor  
  in ovarian cancer effusions, 740  
  in preeclampsia prediction, 430-431
- Viral infections, of central nervous system,  
  molecular diagnosis of, **843-865**  
  enterovirus, 844-851  
  herpes simplex virus, 851-858  
  JC virus, 858-859
- ViroSeq kit, for antiretroviral agent  
  resistance, 917-918
- Virtual Phenotype assay, for antiretroviral  
  agent resistance, 922
- Vitamin B<sub>12</sub> deficiency, cervicovaginal  
  epithelial effects of, 664

- Vitamin C, for preeclampsia prevention, 420
- Vitamin E, for preeclampsia prevention, 420
- Vitronectin, in ovarian cancer effusions, 736
- Vulvar cancer, human papillomavirus in,  
  molecular techniques for, 909-911

---

**W**

- Weight, maternal, prenatal screening and,  
  548
- Western blot test  
  in HIV infection, 303-304  
  in parvovirus infections, 301  
  in prion diseases, 117-118  
  in variant Creutzfeldt-Jakob disease,  
    89, 103
- Williams syndrome, prenatal diagnosis of,  
  474
- Wolf-Hirschhorn syndrome, prenatal  
  diagnosis of, 474

---

**X**

- X chromosomes, markers from, for FISH,  
  476-477
- X-linked disorders, prenatal diagnosis of,  
  488-490

---

**Y**

- Zalcitabine, for HIV infection, resistance to,  
  919
- Zidovudine, for HIV infection, resistance  
  to, 919

